Do you want to help Ectin Research develop the next generation’s cancer therapy?

Ectin Research is currently raising 27 MSEK to finance our upcoming clinical phase I/IIa trial in metastatic bladder cancer patients, starting at the end of 2019/early 2020. The company offers an attractive investment horizon through potential IPO, out-licensing or corporate deal in 2-4 years.
Ectin Research is currently in advanced discussions with specialist and private investors but is interested in attracting additional interest to secure the full amount.
For more details regarding the issue of shares please contact: